Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.
A Quick Reference Guide to Patient Education Materials on Gout
The following websites offer an abundance of options to help your patients understand their disease and learn to live with it. Several sites offer information in various languages, and for your patients who prefer audio-visual to print, one site has several educational videos. The ACR—Diseases and Conditions: Gout (Web page or PDF available in English…
Gout Management Recommendations from the ACR’s 2020 Guideline
The 2020 ACR Guideline for the Management of Gout is intended to provide guidance for the management of patients with gout, and includes recommendations on the indications for and optimal use of urate-lowering therapy (ULT), treatment of gout flares, and lifestyle and other medication recommendations.1 The guideline includes 42 recommendations, of which 16 are strong….
Clinical Insights into Gout Management: Q&A with Dr. Tuhina Neogi
Gout affects more than 9.2 million adults in the U.S. and is the most common form of inflammatory arthritis. This condition and its complications are painful and potentially disabling with varying risk factors. It is characterized by symptoms that are usually sudden, with intense episodes of painful swelling in one or more joints, most often…
Research on Diet & Gout
According to research from Yokose et al. presented at ACR Convergence 2021, regardless of genetic predisposition, diet influences a person’s risk of developing gout.1 Several recent analyses of the Global Burden of Disease (GBD) Study report a disproportionate worsening of gout burden among women, suggesting intensive dietary measures for gout prevention are indicated, especially in…
Highlights from ACR Convergence’s Late-Breaking Abstracts
COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
How to Differentiate Between & Manage Hypereosinophilic Syndromes & EGPA
Hypereosinophilic syndromes and eosinophilic granulomatosis with polyangiitis (EGPA) represent a spectrum of eosinophilic disorders. Amy D. Klion, MD, provided a detailed overview of this spectrum during ACR Convergence 2021.
Multidisciplinary Guidance for Pulmonary Disease in Sjögren’s Syndrome
Lung disease is common, variable and frequently underdiagnosed in patients with Sjögren’s syndrome. An expert pulmonologist and a rheumatologist discussed the diagnosis and management of pulmonary manifestations of Sjögren’s syndrome during ACR Convergence 2021.
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
The Ins & Outs of ILD: The Management & Treatment of ILD in Patients with Rheumatic Disease
Melissa Griffith, MD, discussed the diagnosis and treatment of interstitial lung disease (ILD) in patients with rheumatic diseases, including connective tissue disease and more.
- « Previous Page
- 1
- …
- 39
- 40
- 41
- 42
- 43
- …
- 309
- Next Page »